LPOXY Therapeutics, Inc.

LPOXY Therapeutics, Inc.

"First-ever C. difficile protection for the billions of patients on antibiotic therapy." LPOXY Therapeutics is focused on developing a convenient, orally administered, metered-dose capsule to deliver oxygen directly to the bowel with the aim of preventing Clostridioides difficile colitis and treating inflammatory bowel diseases (IBD). The approach of using oxygen, which has been clinically proven safe and effective, is a novel one. The primary indication for their product is the prevention of the antibiotic-induced superinfection known as Clostridioides difficile colitis, designated by the CDC as an urgent public health threat. Oxygen operates through a triple mechanism of action: it is bacteriostatic to C. difficile, inhibits toxin production, and has anti-inflammatory properties.